Literature DB >> 12829159

Why recent studies relating normal tissue response to individual radiosensitivity might have failed and how new studies should be performed.

Ekkehard Dikomey1, Kerstin Borgmann, John Peacock, Horst Jung.   

Abstract

PURPOSE: New insights into the kinetics of late complications occurring after radiation therapy indicated that all patients have a constant risk of developing late tissue complications. These observations might have a great impact on studies relating normal tissue complications to individual radiosensitivity. METHODS AND MATERIALS: Data previously published by Peacock et al. were used for analysis. In this study, 39 breast cancer patients with severe reactions (responders) were compared with 65 matched patients showing no reactions (nonresponders). Cellular radiosensitivity as measured in vitro in terms of D(0.01) did not show significant differences between the two groups, both for high-dose-rate (5.84 +/- 0.06 vs. 5.85 +/- 0.07 Gy) and low-dose-rate (7.44 +/- 0.10 vs. 7.56 +/- 0.09 Gy) irradiation.
RESULTS: A theoretical distribution was calculated for the individual radiosensitivity of patients with Grade <or= 1, Grade 2, or Grade 3 reactions under the following assumptions: (1). The variation of the individual radiosensitivity is described by a normal distribution. (2). All patients and not only a subgroup have a risk of developing late complications. Based on the normal distribution of low-dose-rate data (mean value [MV] = 7.56 Gy, standard deviation [SD] = 0.5 Gy), a total of 200 hypothetical patients were divided into three groups: a resistant group with a sensitivity >or=(MV + SD), a normal group with a sensitivity between MV - SD and MV + SD, and a sensitive group <or=(MV - SD), the relative fractions being 16%, 68%, and 16%, respectively. It was assumed that these groups differed in the risk of developing late complication; for Grade 3 the annual incidence rate was set at 1%, 2%, and 4% and for Grade 2 at 5%, 10%, and 20% per year, respectively. It was shown that the mean cellular sensitivity calculated for Grade 3 (7.39 +/- 0.10 Gy) or Grade 2 patients (7.46 +/- 0.06 Gy) was slightly but not significantly lower than that of Grade <or= 1 patients (7.65 +/- 0.04 Gy). This result demonstrated that even if the risk was assumed to depend clearly on the individual radiosensitivity, significant differences in the mean cellular sensitivity between responders and nonresponders were not expected, just as found by Peacock et al. It was shown that a significant correlation between these two parameters could be detected only when the risk was analyzed separately for each group of patients.
CONCLUSION: Most data published so far aiming at establishing a relationship between cellular radiosensitivity and the risk of late complications might need to be reevaluated, because the questions asked up to now were inadequate to arrive at a meaningful answer.

Entities:  

Mesh:

Year:  2003        PMID: 12829159     DOI: 10.1016/s0360-3016(03)00188-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  13 in total

1.  Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines.

Authors:  Nifang Niu; Yuxin Qin; Brooke L Fridley; Junmei Hou; Krishna R Kalari; Minjia Zhu; Tse-Yu Wu; Gregory D Jenkins; Anthony Batzler; Liewei Wang
Journal:  Genome Res       Date:  2010-10-05       Impact factor: 9.043

2.  Studies of the in vivo radiosensitivity of human skin fibroblasts.

Authors:  Richard P Hill; Pavel Kaspler; Anthony M Griffin; Brian O'Sullivan; Charles Catton; Hamideh Alasti; Ahmar Abbas; Moustafa Heydarian; Peter Ferguson; Jay S Wunder; Robert S Bell
Journal:  Radiother Oncol       Date:  2007-06-27       Impact factor: 6.280

3.  G2-phase chromosomal radiosensitivity of primary fibroblasts from hereditary retinoblastoma family members and some apparently normal controls.

Authors:  Paul F Wilson; Hatsumi Nagasawa; Markus M Fitzek; John B Little; Joel S Bedford
Journal:  Radiat Res       Date:  2010-01       Impact factor: 2.841

4.  Validation of the cell cycle G(2) delay assay in assessing ionizing radiation sensitivity and breast cancer risk.

Authors:  Jeff W Hill; Kristina Tansavatdi; Kristin L Lockett; Glenn O Allen; Cristiane Takita; Alan Pollack; Jennifer J Hu
Journal:  Cancer Manag Res       Date:  2009-04-30       Impact factor: 3.989

5.  No association between SNPs regulating TGF-β1 secretion and late radiotherapy toxicity to the breast: results from the RAPPER study.

Authors:  Gillian C Barnett; Charlotte E Coles; Neil G Burnet; Paul D P Pharoah; Jennifer Wilkinson; Catharine M L West; Rebecca M Elliott; Caroline Baynes; Alison M Dunning
Journal:  Radiother Oncol       Date:  2010-01-22       Impact factor: 6.280

Review 6.  Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype.

Authors:  Gillian C Barnett; Catherine M L West; Alison M Dunning; Rebecca M Elliott; Charlotte E Coles; Paul D P Pharoah; Neil G Burnet
Journal:  Nat Rev Cancer       Date:  2009-01-16       Impact factor: 60.716

7.  Evaluation of different biomarkers to predict individual radiosensitivity in an inter-laboratory comparison--lessons for future studies.

Authors:  Burkhard Greve; Tobias Bölling; Susanne Amler; Ute Rössler; Maria Gomolka; Claudia Mayer; Odilia Popanda; Kristin Dreffke; Astrid Rickinger; Eberhard Fritz; Friederike Eckardt-Schupp; Christina Sauerland; Herbert Braselmann; Wiebke Sauter; Thomas Illig; Dorothea Riesenbeck; Stefan Könemann; Normann Willich; Simone Mörtl; Hans Theodor Eich; Peter Schmezer
Journal:  PLoS One       Date:  2012-10-23       Impact factor: 3.240

8.  Comparative analysis of three functional predictive assays in lymphocytes of patients with breast and gynaecological cancer treated by radiotherapy.

Authors:  Anna Padjas; Piotr Kedzierawski; Agnieszka Florek; Pawel Kukolowicz; Tomasz Kuszewski; Stanislaw Góźdz; Anna Lankoff; Andrzej Wojcik; Halina Lisowska
Journal:  J Contemp Brachytherapy       Date:  2012-12-28

9.  Analysis of gene expression using gene sets discriminates cancer patients with and without late radiation toxicity.

Authors:  J Peter Svensson; Lukas J A Stalpers; Rebecca E E Esveldt-van Lange; Nicolaas A P Franken; Jaap Haveman; Binie Klein; Ingela Turesson; Harry Vrieling; Micheline Giphart-Gassler
Journal:  PLoS Med       Date:  2006-10       Impact factor: 11.069

10.  Individual radiosensitivity in a breast cancer collective is changed with the patients' age.

Authors:  Judith Auer; Ulrike Keller; Manfred Schmidt; Oliver Ott; Rainer Fietkau; Luitpold V Distel
Journal:  Radiol Oncol       Date:  2014-01-22       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.